These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30934020)

  • 21. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
    Jensen SB; Serre SB; Humes DG; Ramirez S; Li YP; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7426-36. PubMed ID: 26392503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Direct-acting antiviral-resistant variant].
    Imamura M; Chayama K
    Nihon Rinsho; 2015 Feb; 73(2):322-6. PubMed ID: 25764690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
    Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR
    J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
    Wang H; Geng L; Chen BZ; Ji M
    Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.
    Ferraro D; Urone N; Di Marco V; Craxì A
    Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
    Barnard RJ; Howe JA; Ogert RA; Zeuzem S; Poordad F; Gordon SC; Ralston R; Tong X; Sniukiene V; Strizki J; Ryan D; Long J; Qiu P; Brass CA; Albrecht J; Burroughs M; Vuocolo S; Hazuda DJ
    Virology; 2013 Sep; 444(1-2):329-36. PubMed ID: 23876458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.
    Reinharz V; Churkin A; Lewkiewicz S; Dahari H; Barash D
    Bull Math Biol; 2019 Oct; 81(10):3675-3721. PubMed ID: 31338739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks.
    García-Crespo C; Soria ME; Gallego I; Ávila AI; Martínez-González B; Vázquez-Sirvent L; Gómez J; Briones C; Gregori J; Quer J; Perales C; Domingo E
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33121037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escaping stochastic extinction of mutant virus: Temporal pattern of emergence of drug resistance within a host.
    Hayashi R; Iwami S; Iwasa Y
    J Theor Biol; 2022 Mar; 537():111029. PubMed ID: 35077709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of drug resistance during long-acting antimicrobial therapy.
    Nande A; Hill AL
    Proc Biol Sci; 2022 Nov; 289(1986):20221444. PubMed ID: 36350211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PI3K/AKT Pathway and
    Li F; Liu L; Yu X; Rensing C; Wang D
    Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.
    Saha A; Dixit NM
    PLoS Comput Biol; 2020 Nov; 16(11):e1008434. PubMed ID: 33253162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation.
    Wang M; Wang Y; Liu Y; Wang H; Xin X; Li J; Hao Y; Han L; Yu F; Zheng C; Shen C
    PLoS One; 2019; 14(7):e0219989. PubMed ID: 31344133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
    Raja R; Pareek A; Newar K; Dixit NM
    PLoS Pathog; 2019 Apr; 15(4):e1007701. PubMed ID: 30934020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
    Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
    Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.